Floatz logo

Cytosin-Arabinosid

Fit Patients

First Affiliated Hospital of Zhejiang UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Fit Patients cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
French Innovative Leukemia Organisation
Phase 2B
Cyclophosphamide
French Innovative Leukemia Organisation
Phase 2B
Fludarabine
French Innovative Leukemia Organisation
Phase 2B
Ibrutinib
French Innovative Leukemia Organisation
Phase 2B
Venetoclax
First Affiliated Hospital of Zhejiang University
Phase 2B
Gilteritinib
First Affiliated Hospital of Zhejiang University
Phase 2CCC
Gemtuzumab Ozogamicin
First Affiliated Hospital of Zhejiang University
Phase 2CCC
Azacitidine
First Affiliated Hospital of Zhejiang University
Phase 2CCC

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →